Related Experiment Videos
Innovative therapies in wound healing
1Department of Dermatology, Roger Williams Medical Center, Providence, Rhode Island 02908, USA.
Journal of Cutaneous Medicine and Surgery
|April 22, 2003
Summary
Apligraf, a bioengineered skin graft, effectively treats chronic ulcers by delivering growth factors. This innovative treatment shows promise for various acute wound applications.
Area of Science:
- Regenerative Medicine
- Biotechnology
- Dermatology
Background:
- Apligraf is a bioengineered skin substitute utilizing neonatal fibroblasts and keratinocytes.
- Regulatory approval has been granted by the FDA for Apligraf in treating chronic venous and diabetic ulcers.
Purpose of the Study:
- To review the evolution of bioengineered skin technologies.
- To examine the role of growth factors in wound healing.
- To present Apligraf as a case study for bioengineered skin efficacy.
Main Methods:
- Literature review on bioengineered skin development.
- Analysis of cellular mechanisms of growth factors in wound repair.
- Discussion of clinical trial outcomes for Apligraf.
Main Results:
- Bioengineered skin functions as a "smart" delivery system for therapeutic agents.
- Apligraf demonstrates efficacy in treating specific chronic wound types.
Conclusions:
- Bioengineered skin offers a novel therapeutic approach for chronic and diabetic ulcers.
- Potential applications extend to other acute wound management scenarios.